Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum

Simply Wall St.03-09

AdvertisementWhy HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696) Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618622094?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-09 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618622094","market":"sg","top_or_hot":-1,"title":"Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696) Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696) Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320223.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h","article_id":"2618622094","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotechs-valuation-as-hlx11-and-h","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618622094","pubTimestamp":1773058837,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696)\nShanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, including a positive CHMP opinion in Europe for its Perjeta biosimilar HLX11 and progress in its HER2 combination study HLX22 plus HLX87 in China.\nSee our latest analysis for Shanghai Henlius Biotech.\nEven after a 4.42% one day share price decline to HK$65.95, Shanghai Henlius Biotech’s 12.54% year to date share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","02696":"复宏汉霖","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"随着HLX11和HLX22乳腺癌项目获得动力，评估上海复宏汉霖生物的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02696":0.9},"content_text":"AdvertisementWhy HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696) Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, including a positive CHMP opinion in Europe for its Perjeta biosimilar HLX11 and progress in its HER2 combination study HLX22 plus HLX87 in China. See our latest analysis for Shanghai Henlius Biotech. Even after a 4.42% one day share price decline to HK$65.95, Shanghai Henlius Biotech’s 12.54% year to date share price return and very large three year total shareholder return of about 4x suggest interest has been building around its expanding HER2 and biosimilar portfolio. If the momentum in oncology news has you looking wider across healthcare, this is a good moment to scan our screener of 119 healthcare AI stocks for more specialised ideas. With a value score of 5, HK$5,797.88m in revenue and HK$824.30m in net income, plus a share price well below the average analyst target and intrinsic value estimate, is Shanghai Henlius Biotech a mispriced growth story, or is the market already factoring in its next chapter? Price-to-Earnings of 38.5x: Is it justified? On traditional metrics, Shanghai Henlius Biotech screens as good value against peers, with a P/E of 38.5x that sits below both the Asian biotech average and its direct peer group, even though it screens as expensive versus the SWS fair P/E estimate. The P/E ratio compares the current share price with earnings per share and is a quick way of seeing how much investors are paying for each dollar of earnings. For a biotech name with a commercial portfolio and ongoing R&D, a higher P/E can often reflect expectations for future product uptake or pipeline progress rather than just today’s profit line. Here, SWS estimates a fair P/E of 20.6x. This suggests the current 38.5x multiple is rich compared with where the regression based fair ratio might sit if the market moved closer to that level. At the same time, that 38.5x is below the Asian biotech industry average of 39.5x and below the peer average of 54.6x, so the stock is not trading at the top of its group on earnings. Explore the SWS fair ratio for Shanghai Henlius Biotech Result: Price-to-Earnings of 38.5x (ABOUT RIGHT) However, that P/E premium could unwind if HER2 programs face clinical or regulatory setbacks, or if revenue growth of 13.77% and profit growth of 3.66% slow. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another view: DCF says the story is very different While the 38.5x P/E looks slightly rich versus a 20.6x fair ratio, our DCF model paints a contrasting picture. At HK$65.95, the shares are trading about 64% below the SWS DCF fair value estimate of HK$182.99, which raises a clear question: is the market being too cautious about future cash flows? Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 227 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed signals or a clear setup, either way it pays to move quickly and test the story against the numbers yourself. To see how the balance of possible upside and potential downside stacks up for your own portfolio, take a close look at the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop here, you could miss other opportunities that better fit your goals, so use this moment to broaden your watchlist with a few focused screens.  Target long term compounding potential by checking out screener containing 577 high quality undiscovered gems that pair solid fundamentals with quieter market attention. Prioritise sleep at night holdings by reviewing 304 resilient stocks with low risk scores that screen well on resilience and risk scores. Strengthen your core portfolio by focusing on solid balance sheet and fundamentals stocks screener (370 results) that emphasise financial stability and durable fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618622094","isCrawlerRequest":true}